Brokerages Set Personalis, Inc. (NASDAQ:PSNL) PT at $10.57

Personalis, Inc. (NASDAQ:PSNL) has earned a consensus rating of “Moderate Buy” from the eight research firms that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $10.5714.

A number of equities research analysts have recently weighed in on the company. Needham & Company LLC boosted their target price on Personalis from $7.00 to $10.00 and gave the stock a “buy” rating in a research report on Wednesday, November 5th. Morgan Stanley boosted their price objective on Personalis from $9.00 to $11.00 and gave the stock an “equal weight” rating in a report on Monday, December 1st. Lake Street Capital restated a “buy” rating and set a $11.00 target price on shares of Personalis in a research report on Wednesday, November 5th. Guggenheim lifted their price target on shares of Personalis from $6.00 to $12.00 and gave the stock a “buy” rating in a research report on Tuesday, November 11th. Finally, BTIG Research boosted their price target on shares of Personalis from $11.00 to $12.00 and gave the stock a “buy” rating in a research note on Tuesday, November 11th.

Insider Buying and Selling at Personalis

In related news, CEO Christopher M. Hall sold 29,612 shares of the company’s stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $8.99, for a total value of $266,211.88. Following the completion of the sale, the chief executive officer owned 148,486 shares in the company, valued at approximately $1,334,889.14. This represents a 16.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Aaron Tachibana sold 103,668 shares of the stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $10.78, for a total value of $1,117,541.04. Following the completion of the transaction, the chief financial officer directly owned 164,458 shares in the company, valued at $1,772,857.24. The trade was a 38.66% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 3.80% of the company’s stock.

Institutional Trading of Personalis

A number of institutional investors and hedge funds have recently modified their holdings of PSNL. Kennedy Capital Management LLC raised its position in shares of Personalis by 196.2% in the 3rd quarter. Kennedy Capital Management LLC now owns 1,935,078 shares of the company’s stock valued at $12,617,000 after acquiring an additional 1,281,695 shares during the period. Geode Capital Management LLC increased its stake in Personalis by 165.6% in the second quarter. Geode Capital Management LLC now owns 1,365,598 shares of the company’s stock valued at $8,960,000 after purchasing an additional 851,422 shares in the last quarter. ARK Investment Management LLC raised its holdings in Personalis by 11.3% in the third quarter. ARK Investment Management LLC now owns 7,910,191 shares of the company’s stock worth $51,574,000 after purchasing an additional 802,268 shares during the period. Aberdeen Group plc boosted its position in shares of Personalis by 35.7% during the third quarter. Aberdeen Group plc now owns 2,387,947 shares of the company’s stock worth $15,569,000 after purchasing an additional 628,450 shares in the last quarter. Finally, Blue Water Life Science Advisors LP boosted its position in shares of Personalis by 42.6% during the second quarter. Blue Water Life Science Advisors LP now owns 1,676,300 shares of the company’s stock worth $10,997,000 after purchasing an additional 500,900 shares in the last quarter. 61.91% of the stock is owned by institutional investors.

Personalis Trading Up 0.5%

Shares of NASDAQ PSNL opened at $7.97 on Friday. Personalis has a 1-year low of $2.83 and a 1-year high of $11.40. The company has a 50-day moving average of $8.91 and a two-hundred day moving average of $7.17. The company has a market cap of $707.77 million, a PE ratio of -9.06 and a beta of 1.99.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.04. Personalis had a negative net margin of 106.92% and a negative return on equity of 38.25%. The business had revenue of $14.50 million during the quarter, compared to analyst estimates of $13.31 million. As a group, equities research analysts forecast that Personalis will post -1.4 earnings per share for the current year.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.